Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neurofibromatosis 2”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableNot Yet RecruitingNCT07818213
What this trial is testing

How Can the Experience of Hospital Outpatient Departments be Improved?

Who this might be right for
Neurofibromatosis Type 1 (NF1)NF2-related Schwannomatosis
King's College London 30
Not applicableUnknownNCT05685836
What this trial is testing

89Zr-Bevacizumab PET/CT Imaging in NF2 Patients

Who this might be right for
Neurofibromatosis 2
Leiden University Medical Center 15
Not applicableUnknownNCT00004483
What this trial is testing

NF2 Natural History Consortium

Who this might be right for
Schwannoma, VestibularNeurofibromatosis 2Meningioma
House Ear Institute 100
Testing effectiveness (Phase 2)Study completedNCT01661283
What this trial is testing

SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors

Who this might be right for
Malignant Peripheral Nerve Sheath TumorsMPNSTSarcoma
Sarcoma Alliance for Research through Collaboration 25
Large-scale testing (Phase 3)Active Not RecruitingNCT04576117
What this trial is testing

Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

Who this might be right for
Recurrent Low Grade AstrocytomaRecurrent WHO Grade 2 GliomaRefractory Low Grade Astrocytoma+2 more
National Cancer Institute (NCI) 300
Large-scale testing (Phase 3)Active Not RecruitingNCT04924608
What this trial is testing

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas

Who this might be right for
Neurofibromatosis 1Plexiform Neurofibroma (PN)
AstraZeneca 145
Testing effectiveness (Phase 2)WithdrawnNCT03688568
What this trial is testing

Study of Imatinib in Children With Neurofibromatosis and Airway Tumors

Who this might be right for
Neurofibroma, Plexiform
Indiana University
Testing effectiveness (Phase 2)Active Not RecruitingNCT03363217
What this trial is testing

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Who this might be right for
Low-grade GliomaPlexiform NeurofibromaCentral Nervous System Glioma
St. Justine's Hospital 114
Early research (Phase 1)Ended earlyNCT01552434
What this trial is testing

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Who this might be right for
Advanced Malignant NeoplasmCastleman DiseaseDigestive System Carcinoma+36 more
M.D. Anderson Cancer Center 154
Early research (Phase 1)Looking for participantsNCT05873686
What this trial is testing

Clinical Study of NXP900 in Subjects With Advanced Cancers

Who this might be right for
Advanced Solid TumorNSCLC (Non-small Cell Lung Cancer)Renal Cancer+3 more
Nuvectis Pharma, Inc. 140
Testing effectiveness (Phase 2)WithdrawnNCT02986919
What this trial is testing

Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors

Who this might be right for
Peripheral Nerve Tumors
University of Texas Southwestern Medical Center
Testing effectiveness (Phase 2)Study completedNCT01419639
What this trial is testing

Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2

Who this might be right for
Neurofibromatosis Type II
NYU Langone Health 10
Testing effectiveness (Phase 2)Study completedNCT02839720
What this trial is testing

Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma

Who this might be right for
Cutaneous NeurofibromaNeurofibromatosis Type 1Optic Nerve Glioma
National Cancer Institute (NCI) 11
Not applicableStudy completedNCT02246231
What this trial is testing

Effect of Implant Position on Magnetic Resonance Image Distortion

Who this might be right for
Neurofibromatosis Type 2
Manchester University NHS Foundation Trust 5
Early research (Phase 1)Looking for participantsNCT06961565
What this trial is testing

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

Who this might be right for
NF1 MutationNeurofibroma PlexiformNeurofibroma, Plexiform+2 more
Pasithea Therapeutics Corp. 56
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439331
What this trial is testing

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT03190915
What this trial is testing

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Who this might be right for
Juvenile Myelomonocytic LeukemiaNeurofibromatosis Type 1
National Cancer Institute (NCI) 10
Testing effectiveness (Phase 2)Study completedNCT01125046
What this trial is testing

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

Who this might be right for
Acoustic SchwannomaAdult Anaplastic MeningiomaAdult Ependymoma+7 more
Northwestern University 50
Not applicableNo Longer AvailableNCT02589912
What this trial is testing

Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients

Who this might be right for
Neurofibromatosis Type 2Severe Profound Sensorineural Hearing Loss
Massachusetts Eye and Ear Infirmary
Testing effectiveness (Phase 2)Study completedNCT02831257
What this trial is testing

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

Who this might be right for
Neurofibromatosis 2Meningioma
Massachusetts General Hospital 18
Next Page